Standard BioTools Inc
NASDAQ:LAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Standard BioTools Inc
NASDAQ:LAB
|
US |
|
R
|
River Hawk Aviation Inc
OTC:RHWI
|
US |
|
PowerSchool Holdings Inc
NYSE:PWSC
|
US |
|
Irish Residential Properties REIT PLC
F:IRES
|
IE |
|
A
|
Apotea AB (publ)
STO:APOTEA
|
SE |
Standard BioTools Inc
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
Revenue: Q1 2025 revenue was $40.8 million, down 10% year-over-year and in line with expectations.
Guidance Maintained: Full year 2025 revenue guidance remains unchanged at $165 million to $175 million, with revenue expected to be weighted more toward the second half of the year.
Cost Reductions: Non-GAAP operating expenses decreased by 22% year-over-year, driven by $10 million in additional cost reductions this quarter, bringing total annualized savings since the SomaLogic merger to $90 million.
Gross Margin: Non-GAAP gross margin was 53.2%, down from 56.2% last year, mainly due to lower volumes and product mix.
Cash Position: Ended Q1 with $261 million in cash and equivalents and no material debt, with significantly reduced cash burn versus last year.
Instrument Sales: Instrument revenue grew 24% year-over-year in Q1, led by continued success of the Hyperion XTi platform.
Academic Headwinds: Mid-teens percentage decline expected in Americas academic revenue, with ongoing academic funding delays and spending curbs.
M&A Focus: Management confirms a disciplined M&A approach, noting a robust pipeline of potential deals but high standards for execution.
